The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.

Company Guidance -

Q2 2025

During Esperion Therapeutics' first-quarter 2025 earnings call, significant metrics highlighted included a 63% year-over-year total revenue growth to $65 million, excluding a one-time milestone from the previous year. U.S. net product revenue grew 41% year-over-year to $34.9 million, despite a flat lipid market impacted by seasonal Medicare Part D changes and higher patient out-of-pocket costs. The company expanded its field reimbursement support team threefold to enhance physician education on favorable reimbursement landscapes. Esperion's bempedoic acid products, NEXLETOL and NEXLIZET, received notable inclusion in the 2025 ACC-AHA Multi Society Guidelines, providing strong guidance for statin-intolerant patients. Early Q2 2025 trends show prescription growth tracking approximately 8% higher than Q1. The company is also advancing a triple combination therapy anticipated for commercialization in 2027, aiming to lower LDL cholesterol by over 60%. Internationally, royalty revenue from Daiichi Sankyo Europe increased 8% to $10.5 million, showcasing strong global growth. Financially, Esperion ended the quarter with $114.6 million in cash and reiterated its full-year operating expense guidance of $215 million to $235 million.

Significant Revenue Growth

Total revenue for Q1 2025 grew 63% year-over-year to $65 million, after adjusting for a one-time milestone received in Q1 2024. US net product revenue grew 41% year-over-year to $34.9 million.

Expanded Market Access

Field reimbursement support team expanded threefold to 15 payer access specialists, leading to over 30 plans removing prior authorizations and implementing electronic step edits.

Inclusion in ACC-AHA Guidelines

NEXLETOL and NEXLIZET added to the 2025 ACC-AHA Multi Society Guidelines with level 1A and 2A recommendations for patients with acute coronary syndrome.

International Market Growth

Royalty revenue from Daiichi Sankyo Europe increased 8% from Q4 2024 to $10.5 million in Q1 2025. Esperion also entered partnerships with CSL Seqirus in Australia and New Zealand.

Pipeline Advancements

Declaration of lead indication in primary sclerosing cholangitis, targeting a $1 billion market opportunity, reflecting expansion into high-need, high-value indications.

Esperion (ESPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ESPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.15 / -	-0.33	―	―	―
May 06, 2025	2025 (Q1)	-0.15 / -0.21	0.34	-161.76% (-0.55)
Mar 04, 2025	2024 (Q4)	-0.15 / -0.11	-0.5	78.00% (+0.39)
Nov 07, 2024	2024 (Q3)	-0.17 / -0.15	-0.37	59.46% (+0.22)
Aug 12, 2024	2024 (Q2)	-0.17 / -0.33	-0.46	28.26% (+0.13)
May 07, 2024	2024 (Q1)	0.05 / 0.34	-0.79	143.04% (+1.13)
Feb 27, 2024	2023 (Q4)	-0.48 / -0.50	-0.76	34.21% (+0.26)
Nov 07, 2023	2023 (Q3)	-0.43 / -0.37	-0.81	54.32% (+0.44)
Aug 01, 2023	2023 (Q2)	-0.61 / -0.46	-1.05	56.19% (+0.59)
May 09, 2023	2023 (Q1)	-0.65 / -0.79	-0.93	15.05% (+0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ESPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$1.05	$0.98	-6.67%
Mar 04, 2025	$1.58	$1.77	+12.03%
Nov 07, 2024	$2.21	$2.11	-4.52%
Aug 12, 2024	$2.02	$1.84	-8.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Esperion (ESPR) report earnings?

Esperion (ESPR) is schdueled to report earning on Aug 05, 2025, TBA (Confirmed).

What is Esperion (ESPR) earnings time?

Esperion (ESPR) earnings time is at Aug 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ESPR EPS forecast?

ESPR EPS forecast for the fiscal quarter 2025 (Q2) is -0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing